Biocon Receives Health Canada Approval of Bosaya™ and Vevzuo™ (Denosumab biosimilars to Prolia® and Xgeva®) for bone health.

At around 10:42 a.m., Biocon shares were up 1.51 per cent, or Rs 3.6, at Rs 242.05 apiece on BSE. The market capitalisation ...

Biocon Ltd has received approval from Health Canada for its biosimilars, Bosaya and Vevzuo, intended for treating osteoporosis and cancer-related bone complications. This approval underscores Biocon's ...

Bengaluru/Toronto: Biocon is stepping up its global biosimilars play with fresh approvals in Canada, targeting large patient ...

Biocon Ltd.'s shares increased after Health Canada approved two of its denosumab biosimilars for treating osteoporosis and ...

Biocon receives Health Canada's compliance notice for biosimilars Bosaya and Vevzuo, enhancing treatment options for ...

Biocon added 1.66% to Rs 364.45 after the company said that Health Canada has granted a notice of compliance (NOC) for Bosaya (denosumab), a biosimilar to Prolia, and Vezuo (denosumab), a biosimilar ...

The biosimilar fracas targeting AbbVie’s megablockbuster Humira is taking shape. But to Biocon Biologics CEO Shreehas Tambe, the battle doesn’t solely revolve around market share. Humira, also known ...

BENGALURU, India & BRIDGEWATER, N.J.-- (BUSINESS WIRE)--Apr 7, 2026-- ...

Biocon announced that Health Canada has granted a Notice of Compliance (NOC) for Bosaya (denosumab), a biosimilar to Prolia, and Vezuo (denosumab), a biosimilar to Xgeva, on 03 April 2026. Both ...

Profit rises 71% YoY to Rs 144 crore Biocon Biologics share which constitutes 45% of revenues reported 29% YoY growth to Rs ...

Denosumab-based therapies are widely used to increase bone mass, treat osteoporosis, and manage bone complications arising ...